Literature DB >> 28940893

L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey.

S Perez-Lloret1,2, L Negre-Pages3,4, P Damier5, A Delval6, P Derkinderen5, A Destée6, W G Meissner7, F Tison7, O Rascol1.   

Abstract

BACKGROUND AND
PURPOSE: Studies assessing the correlations between L-DOPA-induced dyskinesias (LIDs) and motor fluctuations with health-related quality of life (HRQoL) in Parkinson's disease (PD) have yielded conflicting results. This study aimed to assess the relationship between LIDs and motor fluctuations with HRQoL in patients with PD, and to assess the relative contribution of their severity and duration in a large sample of patients with PD.
METHODS: A total of 683 patients with PD from the COPARK survey were evaluated. HRQoL was assessed using the 39-Item Parkinson's Disease Questionnaire (PDQ-39) (primary outcome) and 36-Item Short Form Survey (SF-36). The daily duration and severity of LIDs were obtained from Unified Parkinson's Disease Rating Scale (UPDRS) IV items 32 and 33, respectively. The daily duration of motor fluctuations was obtained from UPDRS IV item 36 and severity was estimated as the difference between the UPDRS 2 (Activities of Daily Living) score in 'OFF' versus 'ON' condition.
RESULTS: A total of 235 patients with PD (35%) experienced motor fluctuations and 182 (27%) experienced LIDs. The PDQ-39 total and SF-36 physical scores were significantly worse in patients with LIDs, after adjusting for the presence of motor fluctuations. The PDQ-39 total score and SF-36 physical and mental score were significantly worse in patients with motor fluctuations, after adjusting for the presence of LIDs. The severity of LIDs and the duration of motor fluctuations significantly and independently affected PDQ-39 scores. The SF-36 physical score was affected only by the severity of motor fluctuations, whereas the mental score was not affected by any of the aforementioned variables.
CONCLUSION: Our findings suggest that LIDs (mainly their severity) and motor fluctuations (mainly their duration) correlate independently with HRQoL in patients with PD.
© 2017 EAN.

Entities:  

Keywords:  L-DOPA-induced dyskinesia; Parkinson's disease; health-related quality of life; motor complications; motor fluctuations

Mesh:

Substances:

Year:  2017        PMID: 28940893     DOI: 10.1111/ene.13466

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  14 in total

Review 1.  Dyskinesias and levodopa therapy: why wait?

Authors:  Michele Matarazzo; Alexandra Perez-Soriano; A Jon Stoessl
Journal:  J Neural Transm (Vienna)       Date:  2018-02-10       Impact factor: 3.575

Review 2.  Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

3.  Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.

Authors:  Murtadha D Hssayeni; Joohi Jimenez-Shahed; Michelle A Burack; Behnaz Ghoraani
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

4.  Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Gita Vita Soraya; Zulvikar Syambani Ulhaq; Syifaus Shodry; Muhammad A'raaf Sirojan Kusuma; Sarah Herawangsa; Maharani Oryza Sativa; Aridin Gustaf; Dzakky Avecienna Nur Faridwazdi; Shinta Wulandari Florentia; Neila Raisa; Andi Kurnia Bintang; Muhammad Akbar
Journal:  Neurol Sci       Date:  2022-01-25       Impact factor: 3.307

5.  Metabolic Profile in Plasma AND CSF of LEVODOPA-induced Dyskinesia in Parkinson's Disease: Focus on Neuroinflammation.

Authors:  Bruno L Santos-Lobato; Luiz Gustavo Gardinassi; Mariza Bortolanza; Ana Paula Ferranti Peti; Ângela V Pimentel; Lúcia Helena Faccioli; Elaine A Del-Bel; Vitor Tumas
Journal:  Mol Neurobiol       Date:  2021-12-02       Impact factor: 5.590

6.  Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease.

Authors:  Doreen Gruber; Lisa Calmbach; Andrea A Kühn; Patricia Krause; Ute A Kopp; Gerd-Helge Schneider; Andreas Kupsch
Journal:  J Neural Transm (Vienna)       Date:  2019-01-25       Impact factor: 3.575

7.  Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease.

Authors:  Ambica Sethi; Sonam Dilwali; Morgan McCreary; Richard B Dewey
Journal:  Clin Neuropharmacol       Date:  2021 Mar-Apr 01       Impact factor: 1.592

Review 8.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

Review 9.  Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Vibhash D Sharma; Kelly E Lyons; Rajesh Pahwa
Journal:  Ther Clin Risk Manag       Date:  2018-04-12       Impact factor: 2.423

10.  Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson's Disease.

Authors:  Etienne Goubault; Sarah Bogard; Pierre J Blanchet; Erwan Bézard; Claude Vincent; Davide Martino; Justyna Sarna; Oury Monchi; Christian Duval
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.